Skip to content

Shionogi Falls After a Panel Postpones Covid Pill Decision

Signage of Shionogi & Co. atop it's pharmaceutical research center in Toyoanaka, Osaka Prefecture, Japan, on Tuesday, April 26, 2022. The U.S. government has held talks with Shionogi about buying its experimental antiviral pill, people familiar with the matter said last week, yet finding the money to pay for it could be a problem. The drug, which is in late-stage clinical trials, reduced viral loads in patients within the first few days of use in earlier studies.
Signage of Shionogi & Co. atop it's pharmaceutical research center in Toyoanaka, Osaka Prefecture, Japan, on Tuesday, April 26, 2022. The U.S. government has held talks with Shionogi about buying its experimental antiviral pill, people familiar with the matter said last week, yet finding the money to pay for it could be a problem. The drug, which is in late-stage clinical trials, reduced viral loads in patients within the first few days of use in earlier studies.Photographer: Soichiro Koriyama/Bloomberg
Updated on

Shionogi & Co. fell the most in more than two months after health experts postponed a decision on whether to recommend the company’s experimental Covid-19 treatment for use in Japan. Its South Korean partner, Il Dong Pharmaceutical Co.. also plunged. 

Shionogi dropped 5.6% in Tokyo, while Il Dong Pharma was down 17% in Seoul on Thursday. It was their biggest declines since April 13, when questions were raised about the medicine’s impact on fetal development.